Concomitant use of H1 antihistamines improves survival outcomes in cancer patients on immune checkpoint inhibitor therapy: a systematic review and meta-analysis.

Saved in:
Bibliographic Details
Title: Concomitant use of H1 antihistamines improves survival outcomes in cancer patients on immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Authors: de Moraes FCA; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil., de Souza Wagner PH; Department of Medicine, Federal University of Santa Catarina, Florianópolis, Brazil., Hirata RDC; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil., Burbano RMR; Human Cytogenetics Laboratory, Biological Science Institute, Federal University of Pará, Belém, Brazil., Hirata MH; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
Source: Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2026 Jul; Vol. 26 (7), pp. 917-927. Date of Electronic Publication: 2026 Jan 21.
Publication Type: Journal Article; Systematic Review; Meta-Analysis; Review
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1744-8328
DOI:10.1080/14737140.2026.2617952